- Joined
- Nov 2, 2006
- Messages
- 1,047
Is M. avium subspecies paratuberculosis (MAP) the cause of multiple “autoimmune” and “inflammatory” diseases in man? Inferences from the anti-MAP activity of methotrexate, 6-MP, 5-ASA and thalidomide, on MAP in culture.
Interesting !!!! this study shows that most meds given for Crohn's like 5 ASA, meth, and 6 MP have activity against MAP infection also, which may explain why they help??
http://crohn.ie/is-m-avium-subspeci...vity-of-methotrexate-6-mp-5-asa-and-thalidom/
CONCLUSIONS:
We show in vitro heretofore-undescribed inhibition of MAP growth by racaemic thalidomide. Thalidomide (+) is more potent than (-). Of thalidomide’s two moieties, phthalimide has no antiMAP activity and HPD is the active component in inhibiting MAP growth. We suggest that since 1942, initially with 5-ASA, the medical profession has unknowingly been treating MAP infections. These data are compatible with our concern that MAP is zoonotic. We conclude that all idiopathic “autoimmune” and “inflammatory” diseases, empirically treated with medications that we show are active against MAP, should now be evaluated for MAP as the etiological agent.
Interesting !!!! this study shows that most meds given for Crohn's like 5 ASA, meth, and 6 MP have activity against MAP infection also, which may explain why they help??
http://crohn.ie/is-m-avium-subspeci...vity-of-methotrexate-6-mp-5-asa-and-thalidom/
CONCLUSIONS:
We show in vitro heretofore-undescribed inhibition of MAP growth by racaemic thalidomide. Thalidomide (+) is more potent than (-). Of thalidomide’s two moieties, phthalimide has no antiMAP activity and HPD is the active component in inhibiting MAP growth. We suggest that since 1942, initially with 5-ASA, the medical profession has unknowingly been treating MAP infections. These data are compatible with our concern that MAP is zoonotic. We conclude that all idiopathic “autoimmune” and “inflammatory” diseases, empirically treated with medications that we show are active against MAP, should now be evaluated for MAP as the etiological agent.